Sandbox Reserved 1767

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 13: Line 13:
== Structure of Subunits ==
== Structure of Subunits ==
=== SHOC2 ===
=== SHOC2 ===
-
The presence of SHOC2 is essential for complex formation. It a crescent shaped complex that serves as a bridge for PP1C and MRAS, maximizing interaction between the three subunits of the SMP complex. SHOC2 contains a large leucine rich region (LRR) that provides stability and localizes subunit PP1C to the membrane. Houseman SHOC2 only undergoes a 6° conformational change when PP1C and MRAS bind, showing SHOC2 is a scaffolding protein that provides a favorable interface for complex formation. SHOC2 depletion is being studied as a therapeutic approach for RAS-driven cancers due to large scale interactions of the subunits only being made possible due to SHOC2. Hauseman. SHOC2 and PP1C first engage in binding with each other via an N-terminal RVXF motif on SHOC2 that is complimentary to a sequence on PP1C. SHOC2 residues V64 and F66 embed in the complimentary region of PP1C, enhancing SHOC2 affinity for PP1C. SHOC2 bind MRAS-GTP through B strands of a LRR that interacts with a hydrophobic region of MRAS-GTP further stabilizing the complex. KWON
+
The presence of SHOC2 is essential for complex formation. It a crescent shaped complex that serves as a bridge for PP1C and MRAS, maximizing interaction between the three subunits of the SMP complex. SHOC2 contains a large leucine rich region (LRR) that provides stability and localizes subunit PP1C to the membrane. Houseman SHOC2 only undergoes a 6° conformational change when PP1C and MRAS bind, showing SHOC2 is a scaffolding protein that provides a favorable interface for complex formation. SHOC2 depletion is being studied as a therapeutic approach for RAS-driven cancers due to large scale interactions of the subunits only being made possible due to SHOC2. <ref name="Kwon">PMID: 35831509</ref>. SHOC2 and PP1C first engage in binding with each other via an N-terminal RVXF motif on SHOC2 that is complimentary to a sequence on PP1C. SHOC2 residues V64 and F66 embed in the complimentary region of PP1C, enhancing SHOC2 affinity for PP1C. SHOC2 bind MRAS-GTP through B strands of a LRR that interacts with a hydrophobic region of MRAS-GTP further stabilizing the complex. KWON
=== PP1C ===
=== PP1C ===
The Protein phosphatase complex 1 (PP1C) subunit contains the catalytic site of the SMP complex. The PP1C subunit is a phosphatase enzyme responsible for the removal of a phosphate group on an N-terminal phosphoserine (NTpS) on RAF. .<ref name="Liau">PMID: 35768504</ref> This dephosphorylation event allows for pathway activation. PP1C binds to SHOC2 and MRAS-GTP in a specific orientation that leaves this catalytic site accessible for substrate binding. PP1C cannot act independently from the SMP complex because it lacks intrinsic substrate selectivity.<ref name="Liau">PMID: 35768504</ref> Therefore, PP1C requires the presence of SHOC2 and MRAS to function properly, whereas SHOC2 and MRAS may interact in a binary complex without the presence of PP1C <ref name="Hauseman">PMID:35830882</ref> SMP complex formation is initially mediated by SHOC2 and PP1C, then stabilized by the GTP interactions in MRAS and SHOC2.<ref name="Kwon">PMID: 35831509</ref> Similarly to SHOC2, PP1C does not undergo a significant conformational change when SHOC2 and MRAS-GTP bind. The lack of conformational change shows that the structure of PP1C is not dependent on the SMP complex, but in order to act as a phosphatase it must be bound to the complex.<ref name="Liau">PMID: 35768504</ref>. PP1C is involved in many different cellular signaling pathways including protein synthesis, muscle contraction, and even carbohydrate metabolism. Wolfgang It plays an essential role in regulation of many pathways, not just cell proliferation. In all these pathways, including the SMP pathway, PP1C does not exist as a monomer, it is present in holoenzyme form complex with one of two regulatory subunits ensuring there is no sporadic pathway activation. Schulman
The Protein phosphatase complex 1 (PP1C) subunit contains the catalytic site of the SMP complex. The PP1C subunit is a phosphatase enzyme responsible for the removal of a phosphate group on an N-terminal phosphoserine (NTpS) on RAF. .<ref name="Liau">PMID: 35768504</ref> This dephosphorylation event allows for pathway activation. PP1C binds to SHOC2 and MRAS-GTP in a specific orientation that leaves this catalytic site accessible for substrate binding. PP1C cannot act independently from the SMP complex because it lacks intrinsic substrate selectivity.<ref name="Liau">PMID: 35768504</ref> Therefore, PP1C requires the presence of SHOC2 and MRAS to function properly, whereas SHOC2 and MRAS may interact in a binary complex without the presence of PP1C <ref name="Hauseman">PMID:35830882</ref> SMP complex formation is initially mediated by SHOC2 and PP1C, then stabilized by the GTP interactions in MRAS and SHOC2.<ref name="Kwon">PMID: 35831509</ref> Similarly to SHOC2, PP1C does not undergo a significant conformational change when SHOC2 and MRAS-GTP bind. The lack of conformational change shows that the structure of PP1C is not dependent on the SMP complex, but in order to act as a phosphatase it must be bound to the complex.<ref name="Liau">PMID: 35768504</ref>. PP1C is involved in many different cellular signaling pathways including protein synthesis, muscle contraction, and even carbohydrate metabolism. Wolfgang It plays an essential role in regulation of many pathways, not just cell proliferation. In all these pathways, including the SMP pathway, PP1C does not exist as a monomer, it is present in holoenzyme form complex with one of two regulatory subunits ensuring there is no sporadic pathway activation. Schulman
Line 25: Line 25:
Additionally, the surface of MRAS that is buried in the complex overlaps the surfaces used to engage RAF, requiring two separate MRAS proteins to activate a single RAF molecule, one in the SMP complex and one to dephosphorylated Raf to activate the MAPK signaling cascade. The SMP complex is localized to the cell membrane or other RAS isoforms by the palmitoylated, C-terminus end of MRAS.<ref name="Hauseman">PMID:35830882</ref> In its <scene name='95/952694/Cell_membrane/3'>cell membrane bound Ras model</scene>, Ras has an extended, palmitoylated C-terminal helix which allows it to bind to the cell membrane.<ref name="Liau">PMID: 35768504</ref>
Additionally, the surface of MRAS that is buried in the complex overlaps the surfaces used to engage RAF, requiring two separate MRAS proteins to activate a single RAF molecule, one in the SMP complex and one to dephosphorylated Raf to activate the MAPK signaling cascade. The SMP complex is localized to the cell membrane or other RAS isoforms by the palmitoylated, C-terminus end of MRAS.<ref name="Hauseman">PMID:35830882</ref> In its <scene name='95/952694/Cell_membrane/3'>cell membrane bound Ras model</scene>, Ras has an extended, palmitoylated C-terminal helix which allows it to bind to the cell membrane.<ref name="Liau">PMID: 35768504</ref>
 +
 +
 +
=== RAF ===
 +
=== Autoinhibited Confirmation ===
=== Autoinhibited Confirmation ===
Line 31: Line 35:
== Signaling Cascade and Conformational Changes==
== Signaling Cascade and Conformational Changes==
=== Switch I and Switch II ===
=== Switch I and Switch II ===
-
SHOC2-PP1C-MRAS is a regulator of a cell proliferation pathway. Mutations in cell proliferation pathways are responsible for 25% of all cancers 1. If this cell proliferation pathway goes unmediated, rapid cell growth and division will occur; the leading cause of cancers is mutations in this pathway. <ref name="Lavoie">PMID: 35970881</ref> [https://www.nature.com/articles/d41586-022-02189-7 Mechanistic Overview and Signaling Cascade ] shows the pathway SHOC2-PP1C-MRAS is part of. It is a receptor tyrosine kinase pathway.<ref name="Kwon">PMID: 35831509</ref> When MRAS is bound to GDP, the complex is not assembled. SHOC2, PP1C, and MRAS all exist as separate monomers. The Raf domain contains a kinase domain (KD), Ras binding domain (RBD), a C-terminal phosphoserine (CTpS), a N-terminal phosphorylated serine (NTpS), and a 14-3-3 protein dimer, restricting RAF to the cytoplasm. In the activated pathway, MRAS is bound to GTP, and the SMP complex is assembled. PP1C is now in contact with the NTpS, allowing it to become dephosphorylated. <ref name="Lavoie">PMID: 35970881</ref> This dephosphorylation causes the dimerization of two Raf proteins via their kinase domains as well as a conformational change. This conformation change causes the phosphorylation of other residues. Eventually, this leads to the unbinding of GDP from MRAS and the binding of GTP to MRAS, causing a shift from the <scene name='95/952693/Swi_open_conformation/6'>open conformation</scene> to <scene name='95/952693/Switch_i_gtp_bound/11'>closed conformation of SWI.</scene> The Switch I region is made up of residues 42-48 of the MRAS domain.<ref name="Kwon">PMID: 35831509</ref> These residues are crucial for the binding of MRAS, SHOC2, and PP1C. When GDP is bound to the MRAS domain, it is in the <scene name='95/952693/Swi_open_conformation/6'>open conformation.</scene> Since the gamma P is not bound to GDP, there are no hydrogen bond interactions with the oxygens of the phosphate group- hence the open conformation. When GTP is bound to MRAS, it is in the <scene name='95/952693/Switch_i_gtp_bound/11'>closed conformation.</scene> The closed conformation allows for the binding of SHOC2 and PP1C. The open conformation of MRAS sterically clashes with the binding site of SHOC2, which is why the complex is not assembled when GDP is bound. <ref name="Kwon">PMID: 35831509</ref>.
+
SHOC2-PP1C-MRAS is a central gatekeeper in receptor tyrosine kinase signaling 1. Figure 1 shows the specific pathways SHOC2-PP1C-MRAS mediates. When MRAS is bound to GDP, shown in the left of figure 1, Raf is bound to a 14-3-3 protein dimer restricting it to the cytoplasm. When MRAS-GDP is exchanged for GTP via a nucleotide exchange factor GEF, a conformational change occurs. This change figure 2, causes a shift from the open to closed conformation of Switch I. figure 3 Green link The Switch I (SWI) region is made up of residues 42-48 of the MRAS domain. 1 These residues are crucial for the binding of MRAS, SHOC2, and PP1C because MRAS undergoes a conformational change that allows for SMP complex assembly upon GTP binding. Figure 2 When GTP is bound to MRAS, it is in the “closed conformation” because hydrogen bond interactions between the γ phosphate of GTP and residues in the SWI region of MRAS cause SWI to adopt a closed conformation. The closed conformation allows for the binding of SHOC2 and PP1C because there is no steric clash GREEN LINK between the SWI region of MRAS and the surface of SHOC2 when GTP is bound. Green link. The only large-scale conformational change occurs in the MRAS subunit. When GDP is bound to the MRAS domain, it is in the “open” conformation. Green link Since the γ-phosphate is not bound to GDP, there are no hydrogen bond interactions with the oxygens of the γ-phosphate group and the MRAS SWI region, causing MRAS to adpot an "open" conformation. Since SHOC2 and PP1C do not undergo much conformational change, they are in a slow equilibrium of binding and unbinding until MRAS-GTP binds to SHOC2, and the complex is assembled.
-
 
+
take out table as well
[[Image:Table.jpeg|350 px|left|thumb|Figure 1. Residues Interacting at SWI and SWII at subunits SHOC2 and PP1C.<ref name="Liau">PMID: 35768504</ref>.]]
[[Image:Table.jpeg|350 px|left|thumb|Figure 1. Residues Interacting at SWI and SWII at subunits SHOC2 and PP1C.<ref name="Liau">PMID: 35768504</ref>.]]
 +
TAKE out this next paragraph, just don't want to delete green links
Switch I (SWI) and Switch II (SWII) are located between the SHOC2 and MRas subunits. When GTP is hydrolyzed to GDP, Switch I and Switch II relax, in the relaxed state SHOC2 cannot bind to MRas. Two Residues from MRas interact with the gamma phosphate on GTP, changing the complex to the closed confirmation. When GTP is bound to <scene name='95/952694/Mras_switch_i/6'>MRAS at SWI</scene>, it triggers the assembly of the SHOC2 Complex. When SWI is in its open confirmation, PP1C cannot bind with MRas due to the steric clashes, but when GTP binds and SWI is in its closed confirmation, PP1C can bind without hinderance. In a mutated complex, other RAS proteins can replace MRas making cell proliferation more likely. SHOC2-PP1C-MRas may be used as a therapeutic target for cancer treatments through changing the confirmation of the <scene name='95/952694/Mrasswitchii/2'>RAS at SWII</scene>.
Switch I (SWI) and Switch II (SWII) are located between the SHOC2 and MRas subunits. When GTP is hydrolyzed to GDP, Switch I and Switch II relax, in the relaxed state SHOC2 cannot bind to MRas. Two Residues from MRas interact with the gamma phosphate on GTP, changing the complex to the closed confirmation. When GTP is bound to <scene name='95/952694/Mras_switch_i/6'>MRAS at SWI</scene>, it triggers the assembly of the SHOC2 Complex. When SWI is in its open confirmation, PP1C cannot bind with MRas due to the steric clashes, but when GTP binds and SWI is in its closed confirmation, PP1C can bind without hinderance. In a mutated complex, other RAS proteins can replace MRas making cell proliferation more likely. SHOC2-PP1C-MRas may be used as a therapeutic target for cancer treatments through changing the confirmation of the <scene name='95/952694/Mrasswitchii/2'>RAS at SWII</scene>.
Line 57: Line 62:
=== Cancer and Rasopathies ===
=== Cancer and Rasopathies ===
Mutations in any of the 3 subunits of SHOC2-PP1C-MRAS can lead to cancer or a family of developmental disability called Rasopathies. Mutations can occur at any of the SMP interfaces, leading to increased interaction energy and stability.<ref name="Kwon">PMID: 35831509</ref> For SHOC2 and PP1C, common mutations lead to amino acid changes on the interaction surfaces, causing a higher affinity for binding.<ref name="Lavoie">PMID: 35970881</ref> Mutations to MRAS lead to consistent GTP-loading, causing an increase in the formation of the SMP complex and there is consistent activation of the cell-proliferation pathway in the absence of external growth factors. Common mutations in PP1C lead to increased active site activity, causing an increase in the Raf proteins that are active and available to bind to Ras. When the system is unregulated, cells proliferate regardless of external signals, leading to cancer and/or RASopathies.
Mutations in any of the 3 subunits of SHOC2-PP1C-MRAS can lead to cancer or a family of developmental disability called Rasopathies. Mutations can occur at any of the SMP interfaces, leading to increased interaction energy and stability.<ref name="Kwon">PMID: 35831509</ref> For SHOC2 and PP1C, common mutations lead to amino acid changes on the interaction surfaces, causing a higher affinity for binding.<ref name="Lavoie">PMID: 35970881</ref> Mutations to MRAS lead to consistent GTP-loading, causing an increase in the formation of the SMP complex and there is consistent activation of the cell-proliferation pathway in the absence of external growth factors. Common mutations in PP1C lead to increased active site activity, causing an increase in the Raf proteins that are active and available to bind to Ras. When the system is unregulated, cells proliferate regardless of external signals, leading to cancer and/or RASopathies.
- 
-
== Future Directions ==
 
-
The depletion of SHOC2 is being studied as a target for cancer and Rasopathy treatment.<ref name="Kwon">PMID: 35831509</ref> Although MRAS is the protein that triggers the formation of the complex, SHOC2 is the anchoring location for both MRAS and PP1C. Without SHOC2, the complex would not form and Ser259 would not be dephosphorylated. MRAS could be triggered and moved towards the cell membrane, but no complex will form and Raf will remain in the auto-inhibited form. Additionally, there are other RAS proteins that can form an SMP-like complex. If MRAS were to be depleted, other RAS proteins could step in place of MRAS. PP1C is able to dephosphorylated other proteins on it's own, therefore it is not a good target as depletion of PP1C could lead to other issues. Depletion of SHOC2 is the most promising treatment that has been researched. There is also possibility that changing the confirmation of RAS Switch II could lead to decreased cell proliferation.
 
- 
</StructureSection>
</StructureSection>

Revision as of 14:39, 12 April 2023

This Sandbox is Reserved from February 27 through August 31, 2023 for use in the course CH462 Biochemistry II taught by R. Jeremy Johnson at the Butler University, Indianapolis, USA. This reservation includes Sandbox Reserved 1765 through Sandbox Reserved 1795.
To get started:
  • Click the edit this page tab at the top. Save the page after each step, then edit it again.
  • show the Scene authoring tools, create a molecular scene, and save it. Copy the green link into the page.
  • Add a description of your scene. Use the buttons above the wikitext box for bold, italics, links, headlines, etc.

More help: Help:Editing

Contents

SHOC2-PP1C-MRAS

SHOC2-MRAS-PP1C Holophosphatase Complex

Drag the structure with the mouse to rotate

Protopedia Resources

References

  1. 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 Kwon JJ, Hajian B, Bian Y, Young LC, Amor AJ, Fuller JR, Fraley CV, Sykes AM, So J, Pan J, Baker L, Lee SJ, Wheeler DB, Mayhew DL, Persky NS, Yang X, Root DE, Barsotti AM, Stamford AW, Perry CK, Burgin A, McCormick F, Lemke CT, Hahn WC, Aguirre AJ. Structure-function analysis of the SHOC2-MRAS-PP1C holophosphatase complex. Nature. 2022 Jul 13. pii: 10.1038/s41586-022-04928-2. doi:, 10.1038/s41586-022-04928-2. PMID:35831509 doi:http://dx.doi.org/10.1038/s41586-022-04928-2
  2. 2.0 2.1 2.2 2.3 2.4 2.5 2.6 Hauseman ZJ, Fodor M, Dhembi A, Viscomi J, Egli D, Bleu M, Katz S, Park E, Jang DM, Porter KA, Meili F, Guo H, Kerr G, Molle S, Velez-Vega C, Beyer KS, Galli GG, Maira SM, Stams T, Clark K, Eck MJ, Tordella L, Thoma CR, King DA. Structure of the MRAS-SHOC2-PP1C phosphatase complex. Nature. 2022 Jul 13. pii: 10.1038/s41586-022-05086-1. doi:, 10.1038/s41586-022-05086-1. PMID:35830882 doi:http://dx.doi.org/10.1038/s41586-022-05086-1
  3. 3.00 3.01 3.02 3.03 3.04 3.05 3.06 3.07 3.08 3.09 3.10 3.11 3.12 3.13 3.14 3.15 3.16 Liau NPD, Johnson MC, Izadi S, Gerosa L, Hammel M, Bruning JM, Wendorff TJ, Phung W, Hymowitz SG, Sudhamsu J. Structural basis for SHOC2 modulation of RAS signalling. Nature. 2022 Jun 29. pii: 10.1038/s41586-022-04838-3. doi:, 10.1038/s41586-022-04838-3. PMID:35768504 doi:http://dx.doi.org/10.1038/s41586-022-04838-3
  4. 4.0 4.1 Young LC, Hartig N, Boned Del Río I, Sari S, Ringham-Terry B, Wainwright JR, Jones GG, McCormick F, Rodriguez-Viciana P. SHOC2-MRAS-PP1 complex positively regulates RAF activity and contributes to Noonan syndrome pathogenesis. Proc Natl Acad Sci U S A. 2018 Nov 6;115(45):E10576-E10585. PMID:30348783 doi:10.1073/pnas.1720352115
  5. 5.0 5.1 5.2 5.3 Hurley TD, Yang J, Zhang L, Goodwin KD, Zou Q, Cortese M, Dunker AK, DePaoli-Roach AA. Structural basis for regulation of protein phosphatase 1 by inhibitor-2. J Biol Chem. 2007 Sep 28;282(39):28874-83. Epub 2007 Jul 18. PMID:17636256 doi:http://dx.doi.org/10.1074/jbc.M703472200
  6. Lavoie H, Therrien M. Structural keys unlock RAS-MAPK cellular signalling pathway. Nature. 2022 Sep;609(7926):248-249. PMID:35970881 doi:10.1038/d41586-022-02189-7

1. Hauseman ZJ, Fodor M, Dhembi A, Viscomi J, Egli D, Bleu M, Katz S, Park E, Jang DM, Porter KA, Meili F, Guo H, Kerr G, Mollé S, Velez-Vega C, Beyer KS, Galli GG, Maira SM, Stams T, Clark K, Eck MJ, Tordella L, Thoma CR, King DA. Structure of the MRAS-SHOC2-PP1C phosphatase complex. Nature. 2022 Sep;609(7926):416-423. doi: 10.1038/s41586-022-05086-1. Epub 2022 Jul 13. PMID: 35830882; PMCID: PMC9452295.[1].

2. Hurley TD, Yang J, Zhang L, Goodwin KD, Zou Q, Cortese M, Dunker AK, DePaoli-Roach AA. Structural basis for regulation of protein phosphatase 1 by inhibitor-2. J Biol Chem. 2007 Sep 28;282(39):28874-28883. doi: 10.1074/jbc.M703472200. Epub 2007 Jul 18. PMID: 17636256.[2].

3. Kwon JJ, Hajian B, Bian Y, Young LC, Amor AJ, Fuller JR, Fraley CV, Sykes AM, So J, Pan J, Baker L, Lee SJ, Wheeler DB, Mayhew DL, Persky NS, Yang X, Root DE, Barsotti AM, Stamford AW, Perry CK, Burgin A, McCormick F, Lemke CT, Hahn WC, Aguirre AJ. Structure-function analysis of the SHOC2-MRAS-PP1C holophosphatase complex. Nature. 2022 Sep;609(7926):408-415. doi: 10.1038/s41586-022-04928-2. Epub 2022 Jul 13. PMID: 35831509; PMCID: PMC9694338.[3].

4. ​Liau NPD, Johnson MC, Izadi S, Gerosa L, Hammel M, Bruning JM, Wendorff TJ, Phung W, Hymowitz SG, Sudhamsu J. Structural basis for SHOC2 modulation of RAS signalling. Nature. 2022 Sep;609(7926):400-407. doi: 10.1038/s41586-022-04838-3. Epub 2022 Jun 29. PMID: 35768504; PMCID: PMC9452301.[4].

5. Lavoie H, Therrien M. Structural keys unlock RAS-MAPK cellular signalling pathway. Nature. 2022 Sep;609(7926):248-249. doi: 10.1038/d41586-022-02189-7. PMID: 35970881.​[5].

6. Young LC, Hartig N, Boned Del Río I, Sari S, Ringham-Terry B, Wainwright JR, Jones GG, McCormick F, Rodriguez-Viciana P. SHOC2-MRAS-PP1 complex positively regulates RAF activity and contributes to Noonan syndrome pathogenesis. Proc Natl Acad Sci U S A. 2018 Nov 6;115(45):E10576-E10585. doi: 10.1073/pnas.1720352115. Epub 2018 Oct 22. PMID: 30348783; PMCID: PMC6233131.​​[6].

Student Contributors

  • Sloan August
  • Rosa Trippel
  • Kayla Wilhoite
Personal tools